Peptide cycling: is 'on/off' science or folklore?

Where cycling came from

The on/off schedules attached to peptides, eight weeks on and four off, twelve on and six off, did not come from peptide research. They were carried over from anabolic steroid practice, where the reason is specific: exogenous testosterone suppresses the body's own production through the hypothalamic-pituitary-gonadal axis, and time off is meant to allow recovery. Whether that reasoning works for steroids is a separate question, but it is at least a reasoning about a known mechanism.

Applied to peptides, it is a borrowed habit rather than a conclusion. The numbers travelled with the habit: the same eight-and-four and twelve-and-six blocks appear across compounds with nothing in common pharmacologically. The relevant mechanism for most peptides is receptor desensitisation, and the evidence about it points somewhere else.

What receptor desensitisation actually is

Receptors that peptides act on are mostly G-protein-coupled receptors. A 1997 review describes how cellular responses to their agonists are usually attenuated rapidly, through removal of the agonist, receptor phosphorylation and desensitisation, endocytosis and down-regulation (review) ¹. The important word is rapidly: these are processes of minutes to hours at the cell, not a slow exhaustion over weeks.

That matters for the logic of cycling. If a receptor desensitises within hours of continuous exposure and recovers between doses, the variable that matters is how often you dose, not whether you take a month off every quarter. The same review notes that desensitisation, internalisation of receptors and their down-regulation are distinct steps with different timescales, which is why 'tolerance' used loosely covers several different things ¹.

The growth hormone axis: the clearest evidence

The most direct human experiment is old and good. Ten normal men received a six-hour infusion of either saline or GHRH, then a large challenge dose of GHRH or an insulin injection. The growth hormone response to the challenge dose of GHRH was greater after the saline infusion than after the GHRH infusion, so the somatotrophs had become partly refractory. But the response to insulin-induced low blood sugar, a different stimulus, was greater after the GHRH infusion, and the largest secretion of all came during GHRH infusion followed by insulin, showing pituitary reserve had not been depleted (human study) ².

Two conclusions follow, and they pull in different directions from the cycling story. The cells do become less responsive to continued stimulation by the same signal. And they are not exhausted: the hormone is still there and another stimulus releases it.

Secretagogues over weeks

Chronic dosing has been studied too. Normal younger and older men and women received GHRP-2, GHRH or both for 7 to 30 days; chronic administration of either peptide converted the additive response to the combination into a synergistic one, and the authors concluded that whether the growth hormone response desensitises during chronic administration depends in part on the dosage and frequency of administration (human study) ³. Dose and frequency, again, not calendar blocks. Note also what the study measured: the shape of the response to a combination, not a loss of response over a month.

In rat pituitary cells, GHRP-2 and GHRP-6 desensitised the cells to each other but not to GHRH (laboratory study) ⁴. That is a mechanistically interesting point for anyone stacking two secretagogues of the same class: swapping one for another within the class is not a reset.

The longest human data come from MK-677. In a 12-month trial in 563 people with Alzheimer's disease, serum IGF-1 rose 60.1% at six weeks and was still 72.9% above baseline at 12 months of continuous daily dosing (randomised trial) ⁵. The drug failed its clinical endpoints in that trial, but as a measure of whether the axis simply stops responding, a year of daily dosing with IGF-1 still elevated is the answer.

Where desensitisation is the point

One class shows how powerful desensitisation can be when it is pursued deliberately. GnRH receptors are G-protein-coupled receptors on pituitary gonadotrophs, and prolonged activation by GnRH leads to desensitisation and suppressed gonadotrophin secretion, which is the primary mechanism of action of agonist analogues used in prostate cancer, endometriosis and IVF (review) ⁶. Here continuous exposure is the treatment, and taking time off would defeat it.

Our kisspeptin and gonadorelin comparison covers the opposite case, where pulsatile delivery is required to avoid exactly this effect. Both show the same principle: the pattern of delivery decides the result, and the pattern that matters is measured in hours.

How approved peptide medicines are actually dosed

If cycling were necessary, labels would say so. They do not. Tesamorelin, a GHRH analogue, is injected daily and continuously. GLP-1 medicines are taken weekly or daily without scheduled breaks, and the extension of the STEP 1 trial showed what stopping does: 327 participants who had lost a mean 17.3% of body weight over 68 weeks regained 11.6 percentage points of it in the year after withdrawal, and most of the cardiometabolic improvements drifted back towards baseline (randomised trial extension) ⁷. Our half-life and dosing guide sets out the intervals each label specifies and why they differ.

What labels do contain is monitoring and stopping rules: dose reductions for side effects, criteria for discontinuation, and in the growth hormone field, IGF-1 monitoring. Those are clinical decisions based on measurements, not a calendar. Our regulatory tracker records which peptides have an approved label at all, which is the first thing to establish before any schedule is discussed.

Tolerance, tachyphylaxis and what people actually notice

People who cycle often describe a reason: the effect faded. That observation can be real without the explanation being right. Several things fade that are not receptor desensitisation. Early water-weight and appetite changes settle. The novelty of a new routine wears off, and whatever else changed alongside it, sleep, training, diet, drifts back. And where a compound does something measurable, the measurement often has not been taken at all, so the fading is an impression rather than a finding.

The growth hormone evidence is a useful corrective here because it was measured. The response to a repeat GHRH challenge fell, yet the pituitary released more hormone than ever when a different stimulus was applied ², and a year of daily MK-677 still held IGF-1 well above baseline ⁵. If an axis were simply becoming exhausted, neither result would look like that.

The research peptides, where there is nothing to cycle against

For BPC-157, TB-500 and most of the compounds cycling schedules are quoted for, there is no human pharmacology to desensitise. Our BPC-157 entry records what has and has not been studied. A cycle length for a compound with no established human dose, half-life or receptor target is a number without a referent: it cannot be right or wrong because nothing was measured. Sellers and forums supply those numbers anyway, and their confidence is not evidence of anything except repetition.

Why the steroid analogy breaks

It is worth being precise about why the borrowed reasoning does not carry over. Cycling anabolic steroids is about the body's own production shutting down under exogenous hormone, and time off is an attempt to let it restart. Most peptides discussed here are not replacing a hormone; they are stimulating the body to release its own. A growth hormone secretagogue works through the pituitary, which is why the 1986 infusion study could show the gland still full of releasable hormone after the receptor had stopped responding to that particular signal ².

The GnRH agonists are the exception that proves the rule: they do suppress the downstream hormones, powerfully, and nobody cycles them, because suppression is the therapeutic goal ⁶. Where a peptide does suppress something, that is a reason for medical supervision and monitoring, not for a self-scheduled break.

What a scheduled break can cost

Framing use as cycles also hides a cost. For an approved medicine taken for a condition, an unprescribed break is simply an interruption of treatment, and the STEP 1 extension shows how quickly the benefit unwinds ⁷. For an unapproved compound, a cycle schedule can give a false sense that the plan is grounded in something, when the dose, the interval and the break are all invented.

There is a third effect. A cycle invites a restart, and restarting is where dosing errors cluster: new vials, new concentrations, old assumptions. Our reconstitution guide covers where those mistakes happen.

Better questions than 'how long should I cycle?'

• What is the dosing interval that the evidence or label supports, since frequency is what the desensitisation data concern?
• Is there a measurement that tells me whether this is working or overshooting, such as IGF-1 for growth hormone secretagogues?
• What are the stopping rules, meaning the side effects or results that should end use regardless of schedule?
• Is the compound approved for anything at all, and if not, what am I scheduling?

The bottom line

Cycling peptides is folklore in its specifics and half-true in its premise. Receptors do desensitise, and the growth hormone axis demonstrates it clearly, but on a timescale of hours, recoverable between doses, and without exhausting the gland. What the research supports is attention to dose and frequency, and measurements where they exist. What it does not support is any particular number of weeks on followed by any particular number off, because no study we found has tested one.

Frequently asked questions

Do you need to cycle peptides?

We found no trial testing an on/off schedule for any peptide. Approved peptide medicines are dosed continuously according to their labels.

Does the body get used to peptides?

Receptors can desensitise, but in the growth hormone axis this happened within hours of continuous stimulation and the pituitary's reserve stayed intact.

How long can you take MK-677?

In a 12-month trial, IGF-1 was still 72.9% above baseline at a year of daily dosing; that trial missed its clinical endpoints and MK-677 is not approved.

Where did peptide cycling come from?

From anabolic steroid practice, where time off is meant to let suppressed hormone production recover, a different mechanism from receptor desensitisation.

Does switching between similar peptides reset anything?

In rat pituitary cells, two secretagogues of the same class desensitised the cells to each other, so swapping within a class is not a reset.

Related on Grey Peptides

• Half-life and dosing frequency
• MK-677
• Tesamorelin

Sources

1. Böhm, S. K., et al. (1997). Regulatory mechanisms that modulate signalling by G-protein-coupled receptors. Biochem J, 322 ( Pt 1)(Pt 1), 1-18. PMID: 9078236
2. Vance, M. L., et al. (1986). Dual effects of growth hormone (GH)-releasing hormone infusion in normal men: somatotroph desensitization and increase in releasable GH. J Clin Endocrinol Metab, 62(3), 591-4. PMID: 3080467
3. Bowers, C. Y., et al. (1996). GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans. J Pediatr Endocrinol Metab, 9 Suppl 3, 261-70. PMID: 8887169
4. Cheng, J., et al. (1997). Growth hormone releasing peptides: a comparison of the growth hormone releasing activities of GHRP-2 and GHRP-6 in rat primary pituitary cells. Life Sci, 60(16), 1385-92. PMID: 9096259
5. Sevigny, J. J., et al. (2008). Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology, 71(21), 1702-8. PMID: 19015485
6. Ortmann, O., et al. (2002). Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action. Reprod Biomed Online, 5 Suppl 1, 1-7. PMID: 12537774
7. Wilding, J. P. H., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab, 24(8), 1553-1564. PMID: 35441470

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.